OT-101 is a lead clinical-stage antisense RNA therapeutic that targets and inhibits the production of TGF-β2, a cytokine that suppresses the immune system within the tumor microenvironment. Initially developed for solid tumors like high-grade glioma, it is also being investigated as a host-directed therapy for severe viral infections, including COVID-19, by modulating a patient's immune response to the pathogen.